Fairvalue-Calculator Fairvalue-Calculator
EN DE

EPS Bio Technology Corp (4183) Fair Value & Analysis

Healthcare · TW · Market cap 325M TWD

Price14.00 TWD
Fair Value5.64 TWD
Upside-59.7%
Quality95/100
Evidence: Low Range 4.43 TWD – 6.86 TWD

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

EPS Bio Technology Corp (4183) currently trades at 14.00 TWD, while our model-based Fair Value estimate is 5.64 TWD — implying the stock looks roughly 59.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

EPS Bio Technology Corp. manufactures and sells OEM/ODM blood glucose system in Taiwan. It also provides test strip; diabetic self-monitoring blood glucose systems under the EASYMAX and MDT2 BLE name; and wearable, and NFC and Bluetooth connectivity blood glucose monitors. The company was founded in 2006 and is headquartered in Hsinchu City, Taiwan.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -23% Stryker Corporation (S1YK34) -89% Medtronic plc (MDT) -9% Boston Scientific Corporation (B1SX34) -83% Edwards Lifesciences Corporation (EW) -53% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is EPS Bio Technology Corp (4183) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 5.64 TWD versus a price of 14.00 TWD — about −60% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 4183?
Our 21-model fair value for EPS Bio Technology Corp is 5.64 TWD (as of Jun 25, 2026), built from audited fundamentals. The current price is 14.00 TWD.
What is the quality score of 4183?
EPS Bio Technology Corp has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.